Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2012


#146180

54pages

Global Markets Direct

$ 2000

In Stock

 

Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2012

 

Global Markets Directs, 'Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma. Recurrent Head And Neck Cancer Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.
  • A review of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Recurrent Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Recurrent Head And Neck Cancer Squamous Cell Carcinoma 8
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Development by Companies 10
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Products under Development by Companies 15
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Products under Investigation by Universities/Institutes 16
Companies Involved in Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Development 17
Novartis AG 17
ImClone Systems Incorporated 18
Celgene Corporation 19
Merck KGaA 20
PCI Biotech Holding ASA 21
VentiRx Pharmaceuticals, Inc. 22
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
cetuximab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Amphinex + Bleomycin - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Sym-004 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Erbitux + Avastin - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
saracatinib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
everolimus - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Gleevec + Taxotere - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Lenalidomide + Cetuximab - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Tarceva + RAD001 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Cetuximab + Lenalidomide - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Docetaxel + Gemcitabine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
VTX-2337 + Cetuximab - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BYL-719 + Cetuximab - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Drug Profile Updates 48
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Discontinued Products 51
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Dormant Products 52


Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 54
Disclaimer 54


Number of Products Under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2012 8
Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Late Stage Development, H2 2012 12
Comparative Analysis by Mid Clinical Stage Development, H2 2012 13
Comparative Analysis by Early Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Novartis AG, H2 2012 17
ImClone Systems Incorporated, H2 2012 18
Celgene Corporation, H2 2012 19
Merck KGaA, H2 2012 20
PCI Biotech Holding ASA, H2 2012 21
VentiRx Pharmaceuticals, Inc., H2 2012 22
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Stage and Molecule Type, H2 2012 28
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Drug Profile Updates 48
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Discontinued Products 51
Recurrent Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Dormant Products 52


Number of Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma, H2 2012 8
Products under Development for Recurrent Head And Neck Cancer Squamous Cell Carcinoma Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Late Stage Products, H2 2012 12
Mid Clinical Stage Products, H2 2012 13
Early Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 23
Assessment by Combination Products, H2 2012 24
Assessment by Route of Administration, H2 2012 25
Assessment by Stage and Route of Administration, H2 2012 26
Assessment by Molecule Type, H2 2012 27
Assessment by Stage and Molecule Type, H2 2012 28